The Care Economy Is a $648B Market. Here's Why It's Still the Biggest Arbitrage in Venture Capital.

Male venture capitalists have spent the last decade writing checks into SaaS tools that optimize ad spend, automate B2B sales pipelines, and—in several memorable cases—deliver someone else's dog to a groomer on demand. Meanwhile, a $648 billion market sat largely unfunded, under-researched, and dismissed as a "social cause" rather than what it actually is: the largest structural arbitrage in the startup economy.

The Care Economy is not a trend. It is not a "femtech moment." It is a market inefficiency—and the window to build durable, high-margin businesses inside it is open right now, before institutional capital figures out what it's been ignoring.

Today, we are running the numbers on why this is the most interesting investment thesis of the decade, and what it means for founders who are building inside it.

What the Care Economy Actually Is (Precision Required)

The term "care economy" gets used loosely, which is one reason sophisticated investors underestimate its scope. Let's be precise.

The Care Economy encompasses three distinct verticals, each with its own margin profile and addressable market:

• Childcare Infrastructure: Daycare platforms, childcare marketplace tools, employer-sponsored care benefits, and the staffing and credentialing systems that support the $54B U.S. childcare industry alone. Wait-lists at licensed facilities now average 18 months in major metro markets. The supply-demand dislocation is structural, not cyclical.
• Elder Care & Aging Infrastructure: Home health coordination, senior living technology, geriatric care management, and caregiver logistics. With 73 million Baby Boomers moving into peak care-need years and a caregiver workforce that is systematically underpaid and underequipped, the gap between demand and infrastructure is widening by the quarter.
• FemTech: The most visible vertical—reproductive health, menopause care, fertility tracking, maternal mental health, pelvic floor therapy—but also the most misunderstood. FemTech is not a "niche." It addresses biology that affects 51% of the global population across six-plus decades of their lives. The addressable market, globally, runs north of $60B by 2027. The current funding level is a rounding error against that.

Add those three verticals together, layer in adjacent markets—consumer health platforms, caregiver workforce tools, insurance navigation software—and you arrive at the $648B figure. That number comes from McKinsey's 2024 Care Economy analysis. It is not projecting a future state. It is describing the economy that already exists, the one that gets called "women's issues" in board rooms and quietly moves more GDP than the U.S. defense industry.

Why It's Been Systematically Undervalued: The Gatekeeping Math

The Care Economy has been underfunded for an embarrassingly simple reason: the people controlling capital allocation have not needed its products.

Seventy-eight percent of venture capital partners in the United States are men. The subset of those men who have personally navigated a waitlist for childcare, coordinated care for an aging parent, or dealt with a reproductive health system that has produced approximately zero major drug approvals for women's pain management in the last thirty years—that subset is small. The lived knowledge gap produces a valuation gap. The founders pitching these products face a due diligence process conducted by people who are guessing at market size rather than living it.

This creates a specific, measurable distortion: Care Economy companies are consistently undervalued at seed and Series A, then re-rated aggressively upward when they hit revenue milestones that "surprise" investors who didn't believe the market was real.

Maven Clinic went from a $35M Series B in 2020 to a $1.35B valuation by 2023. The market did not change. The investor understanding of the market changed—lagging the founder thesis by three years and several hundred million dollars in missed early-stage entry points.

That lag is the arbitrage. And it remains active.

The Structural Tailwinds That Are Accelerating the Timeline

The Care Economy is not just a market inefficiency waiting to be arbitraged. It has three structural tailwinds that are compressing the timeline for institutional capital to arrive—which means the window for founder-owned, capital-efficient companies to build durable positions is narrowing.

Regulatory pressure: The PUMP Act, expanded postpartum Medicaid coverage, and employer-mandated reproductive health benefits in twenty-two states have created compliance infrastructure needs that didn't exist five years ago. Any mid-market employer with over 500 employees now needs a care benefit vendor. The B2B channel opened.

Workforce economics: The U.S. labor shortage in direct care—home health aides, childcare workers, elder care coordinators—is not recoverable through wage increases alone. The only structural fix is technology that reduces the ratio of care workers to people served. The founders building that technology are addressing a problem that Fortune 500 HR departments are now willing to pay to solve.

Capital-follows-capital dynamics: Blue Pool Capital, GV (Google Ventures), and General Catalyst have all made visible Care Economy investments in the last eighteen months. Once Tier 1 generalist funds make a thesis visible, Tier 2 and Tier 3 follow within 12–18 months. We are in that window now.

The Founder Thesis: What This Means If You're Building Here

If you are a founder operating inside the Care Economy, three strategic imperatives follow from the above.

First: Frame the market correctly in every document you produce. The way you describe your market will determine which investors you attract and at what valuation. "We're building a platform for working mothers" is a $5M seed story. "We're building employer-benefit infrastructure for the $54B childcare market, targeting the 78% of HR decision-makers who currently have no scalable solution" is a $25M Series A story. The underlying company is identical. The market framing determines the room you get into and the multiple you're offered when you exit.

Second: Target the VCs who are already in thesis, not the ones who need to be convinced. Conviction-driven due diligence is faster, valuation anchors higher, and post-investment support is materially better. The Care Economy–focused firms—Operator Collective, BBG Ventures, Amplifyher Ventures—have LPs who want Care Economy exposure. They are not skeptical about market size. They are evaluating your unit economics and team. That is a very different conversation. Most founders waste two quarters pitching generalist firms who need to be educated about the market before they can evaluate the company. That is a tax on your time and your valuation.

Third: Build for profitability early—because the alternative is catastrophic. Care Economy companies that optimize for growth-at-all-costs enter the VC dependency cycle in markets where consumer trust is the moat, not switching costs. If you are operating in reproductive health or elder care and your unit economics require you to raise a Series B within 18 months or the business collapses, you have built a fragile company in a market that cannot afford fragility. The founders who exit well in this space will be the ones who hit profitability at $3M–$5M ARR, used that leverage to negotiate favorable Series A terms, and entered the growth phase owning enough of their cap table to care about the outcome.

The Specific Business Models Generating the Best Returns

Not all Care Economy business models are created equal. The margin profiles vary dramatically, and picking the right structural model before you raise is a decision that compounds for a decade.

The highest-margin positions in the current market are: employer-benefit SaaS (recurring revenue, low churn, enterprise contract structures, B2B sales cycles that are long but predictable), care coordination platforms (marketplace models with network effects—value increases with scale, winner-take-most dynamics in regional markets), and clinical workflow software (serving providers rather than consumers, regulatory moats, high switching costs once integrated into EHR systems).

The lowest-margin, highest-risk positions: direct care delivery. If you are employing care workers, you are in a labor business with wage inflation, regulatory complexity, and thin margins. The technology layer on top of care delivery is valuable. Being the employer of care workers is a different business entirely. Know which company you are building before you take a dollar of capital.

The Honest Assessment

The Care Economy is the highest-signal founder opportunity in the current market because the information asymmetry is real, the tailwinds are structural, and the early institutional capital has arrived without yet pricing the market efficiently. That window does not stay open indefinitely.

The founders who will extract maximum value are the ones who understand they are not building "women's businesses." They are building infrastructure companies in markets that have been structurally underfunded relative to their size—and they are positioning accordingly, targeting the right capital, and building for the profitability that makes them impossible to ignore.

The market doesn't care whether the problem is "important." It responds to margin profiles and defensible positions. The Care Economy has both.

Audit your market framing. Then audit your investor list. Start with whoever told you your market was "niche."